160 related articles for article (PubMed ID: 14669827)
1. Acute decrease in circulating T3 levels enhances, but does not normalise, the GH response to GHRP-6 plus GHRH in thyrotoxicosis.
Nascif SO; Senger MH; Ramos-Dias JC; Lengyel AM
J Endocrinol Invest; 2003 Aug; 26(8):733-7. PubMed ID: 14669827
[TBL] [Abstract][Full Text] [Related]
2. Iopanoic acid-induced decrease of circulating T3 causes a significant increase in GH responsiveness to GH releasing hormone in thyrotoxic patients.
Ramos-Dias JC; Lengyel AM
Clin Endocrinol (Oxf); 1999 Oct; 51(4):461-7. PubMed ID: 10583313
[TBL] [Abstract][Full Text] [Related]
3. Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man.
Pinto AC; Finamor FE; Lengyel AM
Clin Endocrinol (Oxf); 1999 Oct; 51(4):409-14. PubMed ID: 10583306
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus.
Micić D; Macut D; Popović V; Kendereski A; Sumarac-Dumanović M; Zorić S; Dieguez C; Casanueva FF
Metabolism; 1999 Apr; 48(4):525-30. PubMed ID: 10206449
[TBL] [Abstract][Full Text] [Related]
5. Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.
Nascif SO; Correa-Silva SR; Silva MR; Lengyel AM
Pituitary; 2007; 10(1):27-33. PubMed ID: 17410412
[TBL] [Abstract][Full Text] [Related]
6. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
Cordido F; Alvarez-Castro P; Isidro ML; Casanueva FF; Dieguez C
Eur J Endocrinol; 2003 Aug; 149(2):117-22. PubMed ID: 12887288
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
Catalina PF; Mallo F; Andrade MA; García-Mayor RV; Diéguez C
J Clin Endocrinol Metab; 1998 Oct; 83(10):3663-7. PubMed ID: 9768681
[TBL] [Abstract][Full Text] [Related]
8. Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.
Van Dam PS; Smid HE; de Vries WR; Niesink M; Bolscher E; Waasdorp EJ; Dieguez C; Casanueva FF; Koppeschaar HP
J Clin Endocrinol Metab; 2000 Dec; 85(12):4706-11. PubMed ID: 11134132
[TBL] [Abstract][Full Text] [Related]
9. Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment.
Molica P; Nascif SO; Correa-Silva SR; de Sá LB; Vieira JG; Lengyel AM
Pituitary; 2010 Dec; 13(4):315-23. PubMed ID: 20602173
[TBL] [Abstract][Full Text] [Related]
10. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
[TBL] [Abstract][Full Text] [Related]
11. Different growth hormone (GH) response to GH-releasing peptide and GH-releasing hormone in hyperthyroidism.
Ramos-Dias JC; Pimentel-Filho F; Reis AF; Lengyel AM
J Clin Endocrinol Metab; 1996 Apr; 81(4):1343-6. PubMed ID: 8636330
[TBL] [Abstract][Full Text] [Related]
12. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
[TBL] [Abstract][Full Text] [Related]
13. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level.
Popovic V; Damjanovic S; Micic D; Djurovic M; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1995 Mar; 80(3):942-7. PubMed ID: 7883854
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus.
Villas-Boas Weffort RF; Ramos-Dias JC; Chipoch C; Lengyel AM
Metabolism; 1997 Jun; 46(6):706-10. PubMed ID: 9186309
[TBL] [Abstract][Full Text] [Related]
15. Pituitary enlargement due to primary hypothyroidism: growth hormone response to GHRH, GHRP-6 and GHRH plus GHRP-6.
Damjanović S; Popović V; Petakov M; Djurović M; Dieguez C; Casanueva FF
J Pediatr Endocrinol Metab; 1996; 9(5):549-53. PubMed ID: 8961133
[TBL] [Abstract][Full Text] [Related]
16. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
Bowers CY; Granda-Ayala R
Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
[TBL] [Abstract][Full Text] [Related]
19. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.
Popovic V; Leal A; Micic D; Koppeschaar HP; Torres E; Paramo C; Obradovic S; Dieguez C; Casanueva FF
Lancet; 2000 Sep; 356(9236):1137-42. PubMed ID: 11030292
[TBL] [Abstract][Full Text] [Related]
20. Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.
Grugni G; Guzzaloni G; Morabito F
J Endocrinol Invest; 2001 May; 24(5):340-8. PubMed ID: 11407654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
